TOP - July 2022 Vol 15, No 4

Dostarlimab (Jemperli), an anti–PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among 14 patients with mismatch repair-deficient (dMMR) locally advanced rectal cancer, according to the results of a recent clinical trial. Read More ›

The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy. Read More ›

Patients with cancer and immunoglobulin deficiency have compromised immune systems–based response to COVID-19 vaccines. Read More ›

Telehealth is playing a larger role in the delivery of cancer care, but there is more work that needs to be done to permanently increase access, according to a panel of experts during a plenary session at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference. Read More ›

In the July issue of The Oncology Pharmacist (TOP), we feature the latest news and updates relevant to pharmacy professionals working in the field of oncology. Read More ›

Treatment with acalabrutinib (Calquence) elicited a complete or partial response in more than 50% of patients with relapsed or refractory marginal zone lymphoma (MZL), according to interim results of a phase 2 study presented by L. Elizabeth Budde, MD, PhD, Associate Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

Once-daily ibrutinib (Imbruvica) combined with bendamustine (Bendeka) and rituximab (Rituxan; BR) significantly improved progression-free survival (PFS) compared with placebo plus BR in patients aged ≥65 years with newly diagnosed mantle-cell lymphoma (MCL), according to data from the phase 3 SHINE trial. Read More ›

The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment. The Institute of Medicine advises that every cancer survivor receive a survivorship care plan summarizing his or her diagnosis, treatment, and recommendations regarding follow-up care. Read More ›

The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline. Read More ›

Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 ASCO Genitourinary Cancers Symposium. Read More ›